TGTX vs. MOR, RNA, FOLD, ARWR, MRVI, CORT, MRUS, BHC, MLTX, and XENE
Should you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include MorphoSys (MOR), Avidity Biosciences (RNA), Amicus Therapeutics (FOLD), Arrowhead Pharmaceuticals (ARWR), Maravai LifeSciences (MRVI), Corcept Therapeutics (CORT), Merus (MRUS), Bausch Health Companies (BHC), MoonLake Immunotherapeutics (MLTX), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical preparations" industry.
MorphoSys (NASDAQ:MOR) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.
TG Therapeutics received 626 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 76.77% of users gave TG Therapeutics an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.
TG Therapeutics has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
TG Therapeutics has a net margin of 14.24% compared to TG Therapeutics' net margin of -226.79%. MorphoSys' return on equity of 31.34% beat TG Therapeutics' return on equity.
MorphoSys has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.33, suggesting that its share price is 133% more volatile than the S&P 500.
In the previous week, MorphoSys had 8 more articles in the media than TG Therapeutics. MarketBeat recorded 9 mentions for MorphoSys and 1 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.57 beat MorphoSys' score of 0.30 indicating that MorphoSys is being referred to more favorably in the media.
MorphoSys presently has a consensus target price of $11.78, suggesting a potential downside of 38.00%. TG Therapeutics has a consensus target price of $29.83, suggesting a potential upside of 81.03%. Given MorphoSys' stronger consensus rating and higher probable upside, analysts clearly believe TG Therapeutics is more favorable than MorphoSys.
18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 9.2% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
TG Therapeutics beats MorphoSys on 15 of the 18 factors compared between the two stocks.
Get TG Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TG Therapeutics Competitors List
Related Companies and Tools
